BACKGROUND: Infection with parechovirus type 3 (PeV3) can cause severe neurologic and sepsis-like illness in young infants; clinical and epidemiologic descriptions have been limited. We aimed to characterize PeV3 illness and explore risk factors for acquisition in a cluster of neonatal cases at Children's Mercy Hospital in Kansas City, Missouri. METHODS: Cerebrospinal fluid specimens were obtained from infants aged <180 days who were hospitalized with sepsis-like illness or meningitis between June 1 and November 1, 2014. PeV-positive specimens were sequenced at the Centers for Disease Control and Prevention. We reviewed the medical and birth charts of the infants and performed face-to-face parent interviews. We analyzed characteristics according to infant age and intensive care admission status. RESULTS: We identified 35 cases of PeV infection in infants aged 5 to 56 days. Seven infants required intensive care (median age, 11 days vs 27 days among those who did not require intensive care; P = .0044). Six of these 7 infants had neurologic manifestations consistent with seizures, and all 6 of them were treated with acyclovir but subsequently tested negative for herpes simplex virus. Virus sequences formed 2 lineages, both of which were associated with severe illness. Half of the infants were reported to have household contacts who were ill during the week before onset. Infants aged ≤7 days at onset were more likely to have been delivered at the same hospital. CONCLUSIONS: PeV3 can cause severe neurologic illness in neonates, and younger infants are more likely to require intensive care. PeV3 should be considered along with herpes simplex virus and other pathogens when evaluating young infants with sepsis-like illness or meningitis. More widespread testing for PeV3 would enable us to gain a better understanding of the clinical scope and circulation of this virus.
BACKGROUND: Infection with parechovirus type 3 (PeV3) can cause severe neurologic and sepsis-like illness in young infants; clinical and epidemiologic descriptions have been limited. We aimed to characterize PeV3 illness and explore risk factors for acquisition in a cluster of neonatal cases at Children's Mercy Hospital in Kansas City, Missouri. METHODS: Cerebrospinal fluid specimens were obtained from infants aged <180 days who were hospitalized with sepsis-like illness or meningitis between June 1 and November 1, 2014. PeV-positive specimens were sequenced at the Centers for Disease Control and Prevention. We reviewed the medical and birth charts of the infants and performed face-to-face parent interviews. We analyzed characteristics according to infant age and intensive care admission status. RESULTS: We identified 35 cases of PeV infection in infants aged 5 to 56 days. Seven infants required intensive care (median age, 11 days vs 27 days among those who did not require intensive care; P = .0044). Six of these 7 infants had neurologic manifestations consistent with seizures, and all 6 of them were treated with acyclovir but subsequently tested negative for herpes simplex virus. Virus sequences formed 2 lineages, both of which were associated with severe illness. Half of the infants were reported to have household contacts who were ill during the week before onset. Infants aged ≤7 days at onset were more likely to have been delivered at the same hospital. CONCLUSIONS: PeV3 can cause severe neurologic illness in neonates, and younger infants are more likely to require intensive care. PeV3 should be considered along with herpes simplex virus and other pathogens when evaluating young infants with sepsis-like illness or meningitis. More widespread testing for PeV3 would enable us to gain a better understanding of the clinical scope and circulation of this virus.
Authors: Jonathan Davis; Derek Fairley; Sharon Christie; Peter Coyle; Richard Tubman; Michael D Shields Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Justin Sharp; Jeremiah Bell; Christopher J Harrison; W Allan Nix; M Steven Oberste; Rangaraj Selvarangan Journal: J Clin Microbiol Date: 2012-09-26 Impact factor: 5.948
Authors: Malgorzata A Verboon-Maciolek; Floris Groenendaal; Cecil D Hahn; Jonathan Hellmann; Anton M van Loon; Guy Boivin; Linda S de Vries Journal: Ann Neurol Date: 2008-09 Impact factor: 10.422
Authors: Philip N Britton; Russell C Dale; Michael D Nissen; Nigel Crawford; Elizabeth Elliott; Kristine Macartney; Gulam Khandaker; Robert Booy; Cheryl A Jones Journal: Pediatrics Date: 2016-01-20 Impact factor: 7.124
Authors: Gerald Sedmak; W Allan Nix; Jeffrey Jentzen; Thomas E Haupt; Jeffrey P Davis; Sanjib Bhattacharyya; Mark A Pallansch; M Steven Oberste Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Sigrid Baumgarte; Luciano Kleber de Souza Luna; Klaus Grywna; Marcus Panning; Jan Felix Drexler; Claudia Karsten; Hans Iko Huppertz; Christian Drosten Journal: J Clin Microbiol Date: 2007-12-05 Impact factor: 5.948
Authors: Cyril C Y Yip; Kin-Land Lo; Tak-Lun Que; Rodney A Lee; Kwok-Hung Chan; Kwok-Yung Yuen; Patrick C Y Woo; Susanna K P Lau Journal: Virol J Date: 2014-10-18 Impact factor: 4.099
Authors: Glen R Abedi; John T Watson; W Allan Nix; M Steven Oberste; Susan I Gerber Journal: MMWR Morb Mortal Wkly Rep Date: 2018-05-11 Impact factor: 17.586